NLS Pharmaceutics (NASDAQ:NLSP) announces that it has entered into a License Agreement with Novartis Pharma AG, for all of the available data in the original NDA for Sanorex (mazindol) submitted to the U.S. FDA in February 1972
Share your opinion in the comments and support the idea with likes. Thank you for your support!
The information and publications are not meant to be, and do not constitute, financial, investment, trading, or other types of advice or recommendations supplied or endorsed by TradingView. Read more in the Terms of Use.